- Home
- BMO vs BMY Comparison
BMO vs BMY Comparison
Compare BMO & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMO
- BMY
- Stock Information
- Founded
- BMO 1817
- BMY 1887
- Country
- BMO Canada
- BMY United States
- Employees
- BMO N/A
- BMY N/A
- Industry
- BMO Commercial Banks
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- BMO Finance
- BMY Health Care
- Exchange
- BMO Nasdaq
- BMY Nasdaq
- Market Cap
- BMO 93.6B
- BMY 94.0B
- IPO Year
- BMO N/A
- BMY N/A
- Fundamental
- Price
- BMO $126.05
- BMY $43.65
- Analyst Decision
- BMO Hold
- BMY Hold
- Analyst Count
- BMO 1
- BMY 14
- Target Price
- BMO $163.00
- BMY $57.54
- AVG Volume (30 Days)
- BMO 602.8K
- BMY 18.2M
- Earning Date
- BMO 12-04-2025
- BMY 10-30-2025
- Dividend Yield
- BMO 3.64%
- BMY 5.68%
- EPS Growth
- BMO 30.29
- BMY N/A
- EPS
- BMO 8.24
- BMY 2.49
- Revenue
- BMO $22,764,550,743.00
- BMY $47,704,000,000.00
- Revenue This Year
- BMO $24.92
- BMY N/A
- Revenue Next Year
- BMO $3.09
- BMY N/A
- P/E Ratio
- BMO $14.88
- BMY $17.55
- Revenue Growth
- BMO 6.89
- BMY 2.57
- 52 Week Low
- BMO $85.40
- BMY $42.96
- 52 Week High
- BMO $131.37
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- BMO 49.45
- BMY 39.76
- Support Level
- BMO $123.58
- BMY $43.11
- Resistance Level
- BMO $129.31
- BMY $44.24
- Average True Range (ATR)
- BMO 2.07
- BMY 1.03
- MACD
- BMO -0.82
- BMY -0.05
- Stochastic Oscillator
- BMO 32.93
- BMY 9.86
About BMO Bank Of Montreal
Bank of Montreal is a diversified financial-services provider based in North America with over CAD 1.4 trillion in assets. BMO operates four business segments: Canadian personal and commercial banking, US personal and commercial banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the US.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.